Advanced NSCLC Chemotherapy / Biologics

Sort by:
Relevance Thumbs Up Comments Views Newest Oldest
22:29

GRACE

From Bench to Bedside: Genomic Discoveries Driving Lung Cancer Therapies

FEATURING Triparna Sen
  • April 17, 2025
06:03

ecancer

ELCC 2025 Insights: Phase 3 MK-3475A-D77 Trial - SC vs. IV Pembro + Chemo in mNSCLC

FEATURING Enriqueta Felip
  • 6 views
  • April 11, 2025
16:41

Insights from ELCC 2025

ELCC 2025 Summary: Targeted Treatment of RAS-Mutant NSCLC: Adagrasib + Pembro or Fulzerasib + Cetuximab for 1L KRAS G12C; Daraxonrasib Monotherapy for 2L+ Pan-RAS G12X-Cm+ Disease

FEATURING Joop Langen
  • 12 views
  • April 9, 2025
88:00

The Immuno-Oncology Clinical Network (IOCN)

Cases of Immune-Related Hepatitis and Cholangitis in Melanoma and NSCLC

FEATURING Anna Olsson-Brown, Guy Kendall, Ricky Frazer, Trudy Guinan, Lucia Possamai, Claire Barlow
  • 12 views
  • April 4, 2025
05:35

COR2ED The Heart of Medical Education

ELCC 2025 Summary: EGFRm and HER2-Mutated/Overexpressing Advanced NSCLC Updates From Recent Trials

FEATURING Nicolas Girard
  • 33 views
  • April 2, 2025
13:49

GRACE

EGFR and HER2 Targeted Therapies in NSCLC: New Developments and a Changing Landscape

FEATURING Xiuning Le
  • 33 views
  • April 1, 2025
16:26

OncoAlert

Updates in NSCLC: Top Trial Highlights From 2024 (LAURA, CROWN, REACH PC, and MARIPOSA-2)

FEATURING Charu Aggarwal
  • 25 views
  • March 13, 2025
  • 1
04:13

Total Health

91 y/o Female With EGFR M+ NSCLC With Liver Metastasis: Panel Discussion

FEATURING Ramakrishna Battini, Fred Hirsch, David Carbone, Holger Gieschen, Jason Porter
  • 25 views
  • March 13, 2025
11:35

Total Health

Neoadjuvant vs. Adjuvant: A New Paradigm for NSCLC

FEATURING David Carbone
  • 231 views
  • March 8, 2025
  • 1
04:18

Total Health

Preoperative TKIs in Neoadjuvant NSCLC

FEATURING David Carbone
  • 69 views
  • March 8, 2025
41:10

UCLA Health

Unmet Treatment Needs of Chemo-IO in Resectable NSCLC

FEATURING Jay M. Lee
  • 64 views
  • March 8, 2025
31:15

UCLA Health

Current Landscape of Neoadjuvant, Perioperative, and Adjuvant IO in Resectable NSCLC

FEATURING Jay M. Lee
  • 133 views
  • March 8, 2025
  • 2
10:02

Manmeet Ahluwalia

Identifying Patients With EGFR-Mutant mNSCLC Who May Require Treatment Intensification

  • 15 views
  • March 4, 2025
08:52

Won Jin Jeon

Exploring the Time Toxicity of Frontline Regimens for Treatment of EGFR-Mutated NSCLC

  • 17 views
  • March 4, 2025
  • 1
03:25

GRACE

Treatment Options for EGFRm NSCLC: Osimertinib + Chemo (FLAURA2 Trial)

FEATURING Julia Rotow
  • 22 views
  • February 28, 2025
05:32

GRACE

Adjuvant Chemotherapy & Surgery Options for NSCLC Patients

FEATURING Julia Rotow, Ibiayi Dagogo-Jack, Misty Shields, Alissa Cooper, Angel Qin
  • 18 views
  • February 24, 2025
04:51

GRACE

The Future of Lung Cancer Treatment: What’s on the Horizon?

FEATURING Julia Rotow, Ibiayi Dagogo-Jack, Misty Shields, Alissa Cooper, Angel Qin
  • 93 views
  • February 24, 2025
04:43

GRACE

Treatment Options for EGFRm NSCLC: Amivantamab + Lazertinib

FEATURING Julia Rotow
  • 103 views
  • February 21, 2025
06:44

GRACE

EGFRm Lung Cancer: Overview & Treatment Sequence

FEATURING Julia Rotow
  • 205 views
  • February 21, 2025
  • 1
12:16

ecancer

ESMO 2024 Summary: Key Trial Insights on Managing NSCLC With Low PD-L1 Expression

FEATURING Luis Paz-Ares
  • 259 views
  • February 3, 2025
  • 4
02:22

ecancer

ESMO 2024 Review: Amivantamab ± Chemo in EGFRm aNSCLC Post-Osimertinib - MARIPOSA-2 Interim OS

FEATURING Enriqueta Felip
  • 60 views
  • January 21, 2025
06:36

ecancer

WCLC 2024 Review: PAPILLON - TP53 Co-Mutations and ctDNA Clearance in EGFR Ex20ins-Mutated NSCLC

FEATURING Pascale Tomasini
  • 37 views
  • January 21, 2025
11:25

ecancer

ESMO and WCLC Updates on EGFR Exon 20 Insertion in NSCLC: Panel Discussion

FEATURING Antonio Passaro, Pascale Tomasini, Enriqueta Felip, Matthew Krebs
  • 24 views
  • January 21, 2025
28:21

Memorial Sloan Kettering Cancer Center

Role of Surgery in Locally Advanced NSCLC

FEATURING Katherine Gray
  • 279 views
  • January 17, 2025
  • 4
05:00

ecancer

WCLC 2024 Review: FLAURA2 - Tumor Burden, Outcomes, and TP53 Associated Resistance With 1L Osimertinib ± Platinum-Pemetrexed in EGFRm aNSCLC

FEATURING Enriqueta Felip
  • 136 views
  • January 16, 2025

Advanced NSCLC Chemotherapy / Biologics

No subtopics